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Early Diagnosis of Sarcoidosis
Marica Tina Maccarone
Abstract
Sarcoidosis is a rare unknown etiology multisystem inflammatory disease in 
which noncaseating granulomas (a collection of inflammatory cells) forms and 
growth in various organs, involving predominantly lungs, intrathoracic lymph node, 
skin, and eyes. Most commonly, affecting patients between 20 and 40 years old of 
age, although could be observed at any age (female predominance; rare in Asians). 
The areas of the body usually affected by sarcoidosis are lungs, skin, or lymph nodes; 
pulmonary and mediastinal involvement is seen in over 90% of patients. Less com-
monly eyes, liver, heart, and brain are involved. Any organ, however, can be affected. 
Early diagnosis of sarcoidosis can be difficult due to few signs and symptoms in 
its early stages, and when disease does occur, it may mimic other pathologies, and 
it is achieved through chest X-ray, computed tomography (CT)-high resolution 
CT (HRCT), gallium scans. Fluoro-deoxy glucose-positron emission tomography 
(FDG-PET) is another useful tool to assess the extent of disease and has a potential 
to evaluate the clinical management of patients responding or not to the treatment. 
Imaging gives, moreover, an important contribution to the evaluation of prognosis 
and follow-up.
Keywords: sarcoidosis, diagnosis, early diagnosis, chest X-ray, computed 
tomography (CT)-high resolution CT (HRCT), gallium scans, fluoro-deoxy glucose-
positron emission tomography (FDG-PET)
1. Introduction
Sarcoidosis is a rare unknown etiology multiorgan granulomatous disease. The 
most affected organs by the pathology are the lungs, skin, or lymph nodes (espe-
cially intrathoracic lymph nodes). Less commonly are involved eyes, liver, heart, 
and brain, in a percentage ranging between 25 and 50%. Any organ, however, can 
be involved by sarcoidosis [1].
Signs and symptoms depend on which organs are affected and the presentation 
varies with the extent and severity of organ involvement [2].
The first state is asymptomatic phase (incidentally detected on chest imaging), 
approximately in 5% of patients. Then, systemic complaints are possible, which 
manifest itself with fever and anorexia (about 45% of cases). The most common 
condition (about 50% of cases) is pulmonary complaints with clinical presentation 
of dyspnea on exertion, cough, chest pain, and rarely hemoptysis. Pulmonary find-
ings usually are normal but crackles may be audible; furthermore in a little part of 
patients exertional oxygen desaturation may be present [2].
Another possible clinical presentation is Löfgren syndrome, which consists in 
fever, bilateral hilar lymphadenopathy, erythema nodosum (an acute, nodular, 
cutaneous rash), and arthritis with polyarthralgias and is common in Scandinavian 
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patients, but quite uncommon in African-American and Japanese patients. 
Cutaneous involvement may be present not only with erythema nodosum associated 
with Löfgren syndrome, but also with lupus pernio, violaceous rash on the cheeks 
or nose (quite common) and maculopapular plaques (quite uncommon) [2].
Ocular involvement is also possible, which may lead to blindness for untreated 
anterior or (most frequent) posterior granulomatous uveitis, conjunctival lesions 
and scleral plaques.
Other uncommon possible manifestations are [2] nervous system involvement 
with lymphocytic meningitis (rare), cranial nerve palsies, hypothalamic/pitu-
itary dysfunction (rare) with diabetes insipidus and myelopathy; heart failure 
from cardiomyopathy (rare) or heart block and sudden death; osseous involvement 
with arthritic syndromes; blood abnormalities: anemia, leukopenia, thrombocy-
topenia and hemolytic anemia with or without splenomegaly (without spleno-
megaly may reflect bone marrow involvement); gastrointestinal and genitourinary 
involvement (rare): hepatomegaly, cholestasis, portal hypertension, Crohn’s 
disease, pancreatic involvement, nephrocalcinosis, vulva itchiness and male 
infertility (rare); exocrine and endocrine manifestations with hyperprolactinemia, 
amenorrhea, galactorrhea, or nonpuerperal mastitis in women; hypercalciuria 
and hypercalcemia likely result from the increased 1,25-dihydroxy vitamin D 
production (rare) [2].
2. Diagnosis
The diagnosis is based on clinical and imaging features, histological confirma-
tion, and exclusion of other diseases that can create similar histopathological and 
clinical findings.
Imaging is mandatory for diagnosis of sarcoidosis and includes as follows:
• chest radiography (is fundamental for a first evaluation);
• routine chest computed tomography (CT), usually high-resolution CT (HRCT) 
scanning of the chest [2] (has a significantly superior detection rate to chest 
X-ray for mediastinal and pulmonary parenchymal changes and is also useful 
to identify active alveolitis or fibrosis), and the agreement between findings 
and biopsy yield [2]; and
• fluoro-deoxy glucose-positron emission tomography (FDG-PET) combined 
with CT-scan (is fundamental to determinte the extent of organ involvement 
and the disease activity and to evaluate the response to pharmacological 
therapy) [3].
2.1 Chest X-rays and HRCT scan
A correct staging of pulmonary sarcoidosis based on radiological stage of the 
disease is necessary to evaluate the sarcoidosis prognosis [1]. Particularly, there are 
five radiologic stages (forms) of intrathoracic sarcoidosis on chest radiography  
[2–4] as follows:
• Stage 0: normal chest radiographic findings;
• Stage I: bilateral mediastinal lymphadenopathy (hilar lymphadenopathy);
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• Stage II: bilateral mediastinal lymphadenopathy (hilar lymphadenopathy) and 
infiltrates with parenchymal lesion;
• Stage III: infiltrates alone, parenchymal disease only; and
• Stage IV: pulmonary fibrosis.
HRCT, however, is more accurate in identifying the different manifestations of 
pulmonary sarcoidosis as well its complications, but we are still searching for an 
accepted HRCT scoring system.
Main findings of HRCT sarcoidosis are as follows: 
• hilar and/or mediastinal lymph node enlargement (sometimes with calcifica-
tions), classically bilateral hilar and right paratracheal nodal enlargement 
(Garland triad); left paratracheal and aortopulmonary nodes can be also 
enlarged. Atypical pattern of nodal enlargement can be observed in patients 
older than 50 years old of age;
• pulmonary interstitial nodules (micro or macronodules) in a perilymphatic 
distribution;
• thickening of the peribronchovascular interstitium;
• pulmonary ground glass opacity;
• consolidation or large nodular opacities;
• coarse linear opacities, interlobular septal thickening, honeycombing, and 
cysts;
• architectural distortion, superior hilar retraction, or traction bronchiectasis; 
and
• pulmonary fibrosis (Stage IV) with linear bands of fibrosis from hila to all 
directions with distortion of normal lung architecture; honeycombing is rare, 
only in patients with severe fibrosis, mainly in the middle and upper lung 
zones and with subpleural involvement.
Pleural disease is rare and may be observed when disease is extensive.
The diagnosis of pulmonary sarcoidosis requires a compatible clinical picture 
supported by radiologic (X-rays chest and/or HRCT of lungs) and pathologic data 
(pulmonary functional tests and laboratory tests). But for a certain diagnosis, 
biopsy is required in most cases, and endobronchial biopsy via bronchoscopy is 
often performed; its results may be positive even in patients with normal chest 
radiographs. The central histologic finding is the presence of noncaseating granulo-
mas with special stains negative for fungi and mycobacteria [2].
2.2 Cardiopulmonary and laboratory tests
Pulmonary function tests are also routinely used in sarcoidosis for early diag-
nosis and follow-up. They include the evaluation of forced vital capacity (FVC), 
forced expiratory volume in one second (FEV1), the total lung capacity determi-
nation (TLC), vital capacity (VC), residual volume (RV) associated with body 
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plethysmography, and a carbon monoxide diffusion capacity test of the lungs for 
carbon monoxide (DLCO).
Sarcoidosis is commonly considered a restrictive disorder, but more recent stud-
ies are demonstrating some opposite results.
Restrictive disorders (infiltrative) are characterized by a reduction in lung 
volume, with difficult in taking air inside the lungs and decreased total lung 
capacity. Other restrictive disorders are chest wall disorders (neuromuscular, e.g., 
polio, kyphoscoliosis, pleural disease, and severe obesity); chronic interstitial and 
infiltrative disease (pulmonary fibrosis, pneumoconioses, granulomatous diseases, 
pulmonary eosinophilia, and pulmonary alveolar proteinosis); Acute diseases 
(ARDS and infections).
Typical symptoms are dyspnea, tachypnea, end inspiratory crackles without 
airway obstruction, honey-comb lung, secondary pulmonary hypertension, and cor 
pulmonale.
In restrictive pulmonary disease, lung volume is decrease, but flow rate is 
normal as follows:
• TLC decrease;
• RV decrease;
• FEV1 decrease;
• FVC decrease;
• FEV1/VC is equal to or more than 70%;
• DLCO decrease; and
• compliance decrease.
Usually, a significant correlation between radiological stage and pulmonary 
function tests is found.
Cardiopulmonary exercise testing (CPET) is another useful tool to identify 
and quantify the extent of pulmonary involvement and also may suggest cardiac 
involvement that otherwise is not evident [2]. It provides an integrative assess-
ment of involving the pulmonary, cardiovascular, muscular, and cellular oxidative 
systems and involves measurements of gas exchange as follows:
• primarily oxygen uptake (VO2): VO2 at maximal exercise (peak VO2) is consid-
ered the best index of aerobic capacity and cardiorespiratory function;
• carbon dioxide output (VCO2);
• minute ventilation; and
• anaerobic threshold (lactic acid).
In patients who have normal gas exchange at rest, CPET unmasks the gas 
exchange abnormalities.
Laboratory tests can identify some serum abnormalities as high blood calcium 
with a normal parathyroid hormone level and hypercalciuria, or elevated levels of 
angiotensin converting enzyme (ACE) in the blood [1].
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2.3 FDG-PET
FDG-PET is a metabolic imaging technique and provides an insight into 
metabolism of this disease. It relies on the principle of increased accumulation and 
metabolism of glucose by the malignant or inflammatory areas. FDG is a radioac-
tive analog of glucose that enters cells through the same receptors that are involved 
in glucose uptake and gets converted into FDG 6 phosphate by the enzyme hexo-
kinase, similar to glucose metabolism by the glycolytic pathway. FDG 6 phosphate 
is not metabolized further and gets entrapped in the cell. Tissues with high glucose 
metabolism such as brain tissue gray matter, cancer cells, and inflammatory 
changes show increased fluorine – 18 fluorodeoxyglucose ((18) F-FDG) accumula-
tion on PET imaging.
As a key component of the inflammatory process, inflammatory cells consume 
glucose at a much higher level than peripheral noninflammatory cells, leading to 
higher glucose metabolism and increased uptake of (18) F-FDG within inflam-
matory foci. Therefore, the level of FDG uptake is proportional to the level of 
glycolysis in the tissue. This explains the mechanism of increased uptake of FDG in 
malignancy, inflammatory, and infectious processes [3].
The role of fluoro-deoxy glucose-positron emission tomography (FDG-PET) 
scanning in assessing the extent of disease spread or metastasis and its utility in 
assessing response to treatment in the form of chemotherapy or radiotherapy is well 
defined in many neoplastic conditions, and its utility has also been recognized in 
certain inflammatory conditions, like sarcoidosis.
During the last years, FDG-PET imaging has been shown to have a central role to 
detect inflammation activity and has become a novel fundamental tool, playing also 
an increasingly important role in the management of patients with any inflamma-
tory conditions. FDG-PET can afford precious information in patients with pulmo-
nary and extrapulmonary sarcoidosis and has become a centerpiece for testing the 
efficacy of different therapies [5]. In difficult clinical cases, it can also be useful to 
plan the site of biopsy in order to determinate a histopathological diagnosis.
A combined modality using FDG-PET and CT scanning (FDG-PET/CT) has 
been found to be more sensitive than PET in diagnosing. FDG-PET and a combina-
tion of this procedure with computed tomography scanning (FDG-PET/CT) has 
gained prominent attention in patients with sarcoidosis over the last two decades 
as a means to assess disease activity and response to therapy. Radionuclide imag-
ing techniques have increasingly been used in the evaluation of organ involvement 
in sarcoidosis. F-FDG-PET/CT scanning has received increasing attention in last 
several years [3].
The usefulness of F-FDG-PET/CT is to identify the disease activity and the 
extent of organ involvement in patients affected by sarcoidosis; F-FDG-PET/CT is 
still useful to determinate its utility in the evaluation of response to drug treatment, 
comparing the agreement between clinical, radiological (with chest radiography 
and/or HRCT of lungs), and metabolic indices (FDG-PET/CT) of disease activity.
Monitoring disease activity in sarcoidosis still remains a clinical goal as there is no 
gold standard. The term “activity” in sarcoidosis means ongoing inflammation that 
necessitates appropriate drug therapy [3]. PET imaging is a new tool to assess the 
metabolic activity, but there is still limited data on the role of serial PET scans in 
monitoring the sarcoidosis activity [6].
Conventional imaging techniques used in sarcoidosis are chest radiography 
and CT. Even though chest radiography and HR-CT are still the fundamental for 
diagnosing pulmonary involvement, F- FDG PET appears to be superior to both 
techniques to identify active sites of disease. F- FDG- PET also correlates well with 
serum biomarkers, such as soluble interleukin-2 receptor in symptomatic patients, 
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and in lung parenchyma correlates with decrease of lung function values over time. 
Moreover F-FDG-PET even visualizes active lesions (in pulmonary and extrapul-
monary sites) in the context of normal serum biomarkers. Also in cardiac involve-
ment in sarcoidosis, FDG-PET is a promising tool associated or complementary to 
magnetic resonance imaging, especially in planning treatment [7].
Magnetic resonance imaging (MRI) is the main imaging method for diagnosis and 
follow-up of neurosarcoidosis and for evaluation of cardiac involvement. However, 
these mentioned methods are unable to identify active inflammation; instead, FDG-
PET/CT has an important advantage in the detection of reversible, inflammatory, 
active granulomatous disease in patients with sarcoidosis [8].
PET provides high-resolution three-dimensional images of the whole body that 
facilitates precise localization of abnormalities. Localization is enhanced with PET/
CT. Fluorodeoxyglucose is extremely sensitive with a high negative predictive value; 
however, the limiting factor of the test is specificity [9, 10]. (18) F-FDG PET/CT 
allows to obtain a complete morphofunctional cartography of inflammatory active 
localizations and to follow treatment efficacy in patients with sarcoidosis, particu-
larly in atypical, complex, and multisystemic forms.
Disseminated lesions should alert clinician to consider sarcoidosis-lymphoma 
syndrome (SLS) or tuberculosis in the differential diagnosis. However, histological 
confirmation with biopsy will be required in such complex cases.
2.3.1 Pulmonary sarcoidosis
Pulmonary sarcoidosis is the main localization site in the majority of patients 
(>90% cases) typically with bilateral mediastinal (hilar) lymphadenopathy 
diagnosed on chest radiography; and its severity ranges from asymptomatic 
involvement of mediastinal lymph nodes (mostly hilar) to progressive pulmo-
nary fibrosis and chronic respiratory failure that is unresponsive to therapy. The 
most common clinical presentations of pulmonary involvement are cough and 
dyspnea.
The diagnosis of pulmonary sarcoidosis requires a compatible clinical picture 
supported by radiologic (X-rays chest and/or HRCT of lungs) and pathologic data 
(pulmonary functional tests and laboratory tests). A recent innovation in diagnos-
ing of pulmonary sarcoidosis is endobronchial ultrasound that increases the yield of 
transbronchial needle aspiration of hilar and/or mediastinal lymph nodes. F-FDG-
PET is highly sensitive in detecting occult sites of disease and is very useful in 
guiding biopsies of these sites. A combined imaging modality using both FDG-PET 
and CT scan is more sensitive than PET alone and is now the main proceeding of 
care in patients needing biopsies of active lesions [11].
For staging of pulmonary disease on chest radiograph, Scadding stages 
(Figure 1) are still widely used depending on the presence of hilar lymph node 
enlargement and pulmonary opacities on chest radiography as follows:
• Stage 0: normal chest radiographic findings;
• Stage I: bilateral mediastinal lymphadenopathy (hilar lymphadenopathy);
• Stage II: bilateral mediastinal lymphadenopathy (hilar lymphadenopathy) and 
infiltrates with parenchymal lesion;
• Stage III: infiltrates alone, parenchymal disease only; and
• Stage IV: pulmonary fibrosis.
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HRCT, however, is still the gold standard imaging modality for primary diagno-
sis of sarcoidosis and is more accurate than chest X-rays, which is the first imaging 
level, in identifying the different manifestations of pulmonary sarcoidosis as well 
its complications. F-FDG-PET, instead, is a new highly sensitive tool in detecting 
occult sites of disease at the chest CT scan.
HRCT most common signs are: micronodules (miliary sarcoidosis) and macronod-
ules with perilymphatic distribution, for the most part, symmetrically in the middle 
zones of the lungs; rarely solitary opacity (alveolar sarcoidosis) and with a mass-like 
presentation (1–4 cm in diameter) may mimic consolidation containing air broncho-
grams, from confluence of many smaller nodules with irregular margins and present-
ing as sarcoid galaxy sign (mass-like region from confluence of numerous smaller 
granulomas with a central core and multiple peripheral nodules; central cavitation 
may occur, and the lesion can be surrounded by ground-glass opacity), more frequent 
in patients older than 50 years of age of presentation; linear opacities, mostly, in the 
upper and middle parts of the lungs, most common of stage II or III of disease; and 
ground glass opacities represent interstitial sarcoid granulomas under resolution rather 
than alveolitis, above all, located in the lower zones of the lungs [12] (Figures 2–6).
Functional imaging of sarcoidosis nowadays is performed with (18) F-FDG 
PET-CT, which improves anatomical localization of sites of abnormality and has a 
relatively short delay time between radiotracer injection and image acquisition. (18) 
F-FDG PET-CT can identify disease activity better than conventional makers in a 
large proportion of patients (very high sensitivity about 80–100%). In patients with 
positive HRCT but no parenchymal fluorodeoxyglucose F18 uptake, pay attention to 
initiation or intensification of immunosuppressive treatment [1, 13].
2.3.2 Cardiac sarcoidosis
Cardiac involvement in sarcoidosis is uncommon (5%) and is associated with 
very poor prognosis [1], because of many complications of cardiac as follows: 
ventricular tachycardia, conductional abnormalities, congestive heart failure, and 
sudden cardiac death. Moreover, cardiac sarcoidosis (CS) is an important prog-
nostic factor in patients with this disease. However, early diagnosis of CS in still 
Figure 1. 
Chest X-rays: reticulonodular pattern with perihilar distribution.
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really difficult due to the nonspecific clinical manifestations of the disease, inho-
mogeneous myocardial involvement, and the limited diagnostic yield of diagnostic 
tests. Therefore, there are no standardized tests for the early diagnosis of cardiac 
sarcoidosis, although early detection of CS is very important for effective treat-
ment. Besides a history and physical examination, electrocardiography (ECG) and 
transthoracic echocardiography are useful for cardiac evaluation.
Figure 2. 
HRCT: coarse linear opacities, architectural distortion, superior hilar retraction, and traction bronchiectasis.
Figure 3. 
HRCT: hilar and mediastinal lymph node enlargement, sometimes with calcification.
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CS can be diagnosed using (18) F-FDG-PET/CT (PET) and cardiovascular mag-
netic resonance (CMRI) that nowadays have been emerged as well for this purpose in 
recent clinical practice [1]. Imaging modalities that can both identify disease and pre-
dict response to therapy are supreme to improve management of cardiac sarcoidosis.
(18) F-FDG-PET has many practical advantages in identifying disease activ-
ity and monitoring treatment response in patients with CS [1]. In (18) F-FDG, 
increased uptake, indicating active inflammation, can be seen in CS in the 
 myocardial wall [14, 15].
Figure 4. 
Scadding stages for staging of pulmonary disease on chest X-rays.
Figure 5. 
HRCT: micronodules and macronodules with perilymphatic distribution, for the most part, symmetrically 
in the middle zones of the lungs; pulmonary ground glass areas; thickening of the peribronchovascular 
interstitium; coarse linear opacities and interlobular septal thickening; and architectural distortion, superior 
hilar retraction, and traction bronchiectasis.
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Focal hypermetabolic activity or a focal increase of activity with a diffusely 
increased background on (18) F-FDG- PET is characteristic for cardiac sarcoidosis 
but this technique has some limitations. Normal myocardial cells use glucose as 
one of main energy substrates [14], and so physiologic (18) F-FDG uptake may be 
found in myocardium of healthy subjects; also papillary muscles and lateral wall 
of left ventricle may also show normal uptake of (18) F-FDG. Then, special patient 
preparation is, therefore, needed prior to F-FDG-PET scan in patients with sarcoid-
osis, with three different approaches: prolonged fasting, dietary modification with 
high-fat diet and i.v. administration of unfractionated heparin, trying to suppress 
(18) F-FDG uptake promoting fatty acid metabolism.
In cardiac sarcoidosis, the combined use of FDG-PET/CT and CMRI may 
provide optimal detection of the disease by enabling the differentiation between 
patients with active granulomatous inflammation and those with fibrous lesions. 
CMRI is a sensitive technique to assess the locations and extent of disease. 
Myocardial sarcoidosis may present on CMRI as segmental wall motion abnormal-
ity, focal wall thickening or thinning, or nodules with a patchy distribution [3].
On CMRI scan, in CS, we can find late gadolinium enhancement (LGE) related 
to the presence of fibrous granulomatous tissue, areas with an increased signal on 
T2-weighted sequences consistent with myocardial edema and with hypointensity 
suggesting fibrosis [10]. Recently, the value of LGE on CMRI, which allows visu-
alization of even minute amounts of myocardial damage, has been emphasized in 
diagnosing CS, and it might be a promising tool for determining the prognosis of 
patients with biopsy-proven extracardiac sarcoidosis [1, 16].
However, it is not easy to differentiate between active and inactive sarcoidosis 
lesions, which is important for patient management. In addition, cardiac MRI is 
generally contraindicated in patients with pacemakers or implantable cardioverter 
defibrillators (ICDs).
2.3.3 Neurosarcoidosis
Nervous system involvement is not an uncommon manifestation of sarcoidosis 
and can be clinically symptomatic neurosarcoidosis, which occurs in 5–16% of 
Figure 6. 
Sarcoid galaxy sign: mass-like region from confluence of numerous smaller granulomas with a central core 
and multiple peripheral nodules (arrows).
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patients with sarcoidosis, and subclinical neurosarcoidosis, with an incidence of 
subclinical disease that may be higher [17–19]. The neurological manifestations 
depend on the areas of the nervous system involved.
The most commonly involved part are cranial nerves, though any part of neu-
roaxis can be affected. The facial nerve is the most common cranial nerve involved 
presenting with facial palsy, and the second most common nerve affected is the 
optic nerve presenting with diplopia or impaired visual acuity [3, 19].
Neurosarcoidosis in the brain can present with leptomeningeal and intraparen-
chymal infiltration of granulomas resulting, for example, in cranial nerve palsies, 
basal meningitis, and endocrine dysfunction. It can cause also peripheral neuropa-
thies (such as sensorimotor polyneuropathy, radiculopathy, and myopathy) [3]. 
For all of these reasons, neurosarcoidosis is an important cause of morbidity and 
mortality in patients with sarcoidosis.
Diagnosis and management of patients with neurosarcoidosis are still challeng-
ing because the gold standard is tissue-proven biopsy but, in most cases of nervous 
system involvement, it is really difficult to obtain [3, 18].
Contrast-enhanced MRI for the detection of intracranial and spinal cord lesions 
is the imaging modality of choice for evaluating neurosarcoidosis. However, the 
findings on MRI are often nonspecific.
In central nervous system (CNS) involvement, the hypointensity of signal of 
the dural and of parenchymal lesions in T2-weighted sequences is useful to identify 
sarcoidosis. Contrast-enhanced MRI is a sensitive tool in the detection of CNS 
inflammation but has a low specificity, making the correct diagnosis of neurosar-
coidosis still a clinical challenge.
The most common imaging finding in T2-weighted sequences are hyperintense 
parenchymal lesions (gray matter) and in T1-weighted sequences, after intravascular 
administration of contrast agents, are meningeal enhancement (basilar meningitis 
involving of cranial nerves is thought to be a common phenomenon), and swelling and/
or enhancement of optic nerves or chiasm maybe with associated visual loss. Other 
imaging presentations include intracranial masses simulating neoplasms and vasculitic 
infarcts. Moreover, in a small part of cases, brain MRI can be normal. Cervical or tho-
racolumbar spine abnormalities, such as spinal cord swelling, meningeal enhancement, 
and parenchymal contrast enhancing lesions, can also be detected [20].
Electromyography (EMG) can be an additional useful tool for peripheral 
neuropathy evaluation, although the findings are not specific.
The usefulness of (18) F-FDG in neurosarcoidosis is poor because of the physi-
ologic uptake of (18) F-FDG activity in normal gray matter. However, granuloma-
tous inflammation shows hypermetabolism, whereas neuronal damage presents as 
hypometabolism. (18) F-FDG-PET may reveal additional occult lesions amenable to 
biopsy in some patients with inaccessible intracranial lesions, but the literature on 
(18) F-FDG and neurosarcoidosis is very limited.
2.3.4 Bone sarcoidosis
Bone involvement is a rare manifestation of sarcoidosis usually associated with pul-
monary findings. The exact prevalence of bone sarcoidosis is still not known, depend-
ing on the studied population and the used diagnostic tools [21]. The  prevalence of 
bone sarcoidosis is between 3% and 5%, above all affecting the phalanges [22].
Both (18)F-FDG-PET/CT and conventional MRI are sensitive in detecting sar-
coidosis bone lesions but are not always reliable in differentiating sarcoidosis bone 
lesions from metastatic disease, thus often requiring bone biopsy [17].
(18) F-FDG-PET/CT is highly sensitive in detecting granulomatous bone 
marrow infiltration, but an increased (18) F-FDG uptake can mimic metastatic 
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disease, reducing the specificity of (18) F-FDG-PET/CT when both sarcoidosis 
and a tumor, which may develop bone metastases, occur in the same patient. Bone 
assessment in sarcoidosis patients is also performed using MRI, commonly relying 
on T1-weighted and T2-weighted images. However, routine MRI is not reliable in 
differentiating sarcoidosis bone lesions from metastatic disease [17].
Multifocal skeletal sarcoidosis may present as a false positive for bone metastases on 
(18) F-FDG PET/CT since granulomatous bone marrow infiltration may have an uptake 
of (18) F-FDG, which mimics that of metastatic disease. When false positive findings 
on (18) F-FDG PET/CT cannot be totally excluded, biopsy or MRI may represent the 
second choice to achieve diagnosis. Since conventional MRI may not be accurate in 
distinguishing between sarcoidosis and metastatic bone lesions, it is possible to perform 
diffusion whole-body MRI: T1-weighted, T2-weighted STIR, and diffusion-weighted 
imaging (with different b values) [17]. The latter is able to evaluate microscopic tissue 
water motions average at the millimeter scale of MR images. The ADC value reflects the 
degree of freedom of water movement at the cellular level, which is determined by archi-
tectural tissue properties such as cellular density, cellular arrangements, vascularity, 
extracellular space tissue viscosity, and nuclear/cytoplasmic ratio. Water movement is 
impeded in many tumors because of their high cellular density and T2 relaxation times, 
resulting in high signal intensity on diffusion-weighted images and low ADC values [1].
On conventional imaging the pelvic bone lesions appeared with a signal pattern not 
specific for sarcoidosis bone lesions or metastatic disease (low signal on T1-weighted 
images and high signal on STIR images). On diffusion-weighted imaging the pelvic 
bone lesions showed high signal, which is often seen in bone metastases, but the ADC 
(<700 µm2/s) was too low to be suspicious for metastases from breast cancer [1], which 
enables to differentiate normal bone marrow from malignant marrow [17, 23, 24].
3. Conclusions
Imaging gives an important contribution to the assessment of prognosis and 
follow-up in sarcoidosis. FDG-PET/CT is routinely used for the diagnosis, stag-
ing, and therapeutic assessment of several malignancies and becomes nowadays a 
relevant tool for the management of several infectious and inflammatory diseases, 
such as sarcoidosis. PET can also be a useful tool for the diagnosis of sarcoidosis by 
identifying potential biopsy sites in organs that might be accessible. FDG-PET/CT 
plays a crucial role in sarcoidosis disease, especially for the diagnosis of potentially 
rare extrapulmonary involvement, and is also an interesting tool for assessing 
therapeutic efficacy of inflammatory diseases and for management of patients.
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